BlackRock Inc (BLK)vsJohnson & Johnson (JNJ)
BLK
BlackRock Inc
$1,084.83
+1.60%
FINANCIAL SERVICES · Cap: $165.75B
JNJ
Johnson & Johnson
$221.32
-0.53%
HEALTHCARE · Cap: $535.63B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 276% more annual revenue ($96.36B vs $25.64B). BLK leads profitability with a 24.4% profit margin vs 21.8%. BLK appears more attractively valued with a PEG of 1.33. BLK earns a higher WallStSmart Score of 78/100 (B+).
BLK
Strong Buy78
out of 100
Grade: B+
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BLK.
Margin of Safety
-37.5%
Fair Value
$160.99
Current Price
$221.32
$60.33 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.6%
Large-cap with strong market position
Keeps 24 of every $100 in revenue as profit
Revenue surging 27.0% year-over-year
Earnings expanding 45.9% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
Moderate valuation
Weak financial health signals
Negative free cash flow — burning cash
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : BLK
The strongest argument for BLK centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 24.4% and operating margin at 35.6%. Revenue growth of 27.0% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : BLK
The primary concerns for BLK are P/E Ratio, Piotroski F-Score, Free Cash Flow.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
BLK profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
BLK carries more volatility with a beta of 1.46 — expect wider price swings.
BLK is growing revenue faster at 27.0% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
BLK scores higher overall (78/100 vs 59/100), backed by strong 24.4% margins and 27.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BlackRock Inc
FINANCIAL SERVICES · ASSET MANAGEMENT · USA
BlackRock, Inc. is an American multinational investment management corporation based in New York City.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other ASSET MANAGEMENT Stocks
Want to dig deeper into these stocks?